A new kind of pharmaceutical company is launched from Geneva. Created by the Geneva-based venture capital company Medicxi, Centessa Pharmaceuticals will only invest in biotechnology companies developing a single molecule. Based in Cambridge, Mass., This new pharma has raised $ 250 million from some of the largest specialty investors.
Centessa Pharmaceuticals will use the so-called “asset centric” investment strategy developed by, one of Europe’s largest life science venture capital firms, according to a press release sent on Tuesday. Concretely, “each biotech in which Centessa invests will constitute an independent operational unit focused on a product; the decisions to continue or to stop research will be taken only on the basis of the data of each molecule, ”explains Francesco de Rubertis, co-founder of Medicxi and creator of Centessa, a project he launched in mid-September 2020.